GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
GenMark Diagnostics (GNMK) PT Lowered to $8 at Cowen; 'Bar is Low from Here'
February 28, 2018 6:43 AM ESTCowen lowered its price target on GenMark Diagnostics (NASDAQ: GNMK) to $8.00 (from $10.00) while maintaining an Outperform rating following Q4 results.
Analyst Doug Schenkel commented, "Q4 revenue was solid, but gross margins came up light. '18 revenue guidance was as expected, but... More
